Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin's disease

American Journal of Medicine

Volumn 102, Issue 1, 1997, Pages 21-28

  Seymour, J F ^a   Talpaz, M ^a   Hagemeister, F B ^a   Cabanillas, F ^a   Kurzrock, R ^a  

^a Box # 302 ^*

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; INTERLEUKIN 6;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; THROMBOCYTE COUNT; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; BETA 2-MICROGLOBULIN; BLOOD SEDIMENTATION; FEMALE; HODGKIN DISEASE; HUMANS; INTERLEUKIN-6; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SERUM ALBUMIN;

EID: 0031046182     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00352-X     Document Type: Article

References (66)

1. Kaufman D, Longo DL. Hodgkin's disease. Crit Rev Oncol Hematol. 1992;13:135-142.
2. De Vita VT Jr, Hellman S, Jaffe ES. Hodgkin's disease. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology. Philadelphia, PA: Lippincott; 1993:1819.
3. Longo DL. The use of chemotherapy in the treatment of Hodgkin's disease. Semin Oncol. 1990;17:716-721.
4. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. NEJM. 1992;327:1478-1484.
5. Specht L. Prognostic factors in Hodgkin's disease. Cancer Treat Rev. 1991;18:21-28.
6. Proctor SJ, Taylor PRA. Classical staging of Hodgkin's disease is inappropriate for selecting patients for clinical trials of intensive therapy: the case for the objective use of prognostic factor information in addition to classical staging. Leukemia. 1993;7:1911-1917.
7. Jücker M, Abts H, Li W, et al. Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. Blood. 1991;77:2413-2420.
8. Klein S, Jücker M, Diehl V, Tesch H. Production of multiple cytokines by Hodgkin's disease derived cell lines. Hematol Oncol. 1992;10:319-324.
9. Hsu S-M, Xie S-S, Hsu P-L, Waldron JA Jr. Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease. Am J Path. 1992; 141:129-134.
10. Tesch H, Feller AC, Jücker M, et al. Activation of cytokines in Hodgkin's disease. Ann Oncol. 1992;3(suppl 4):S13-18.
11. Ni K, O'Neill HC. Proliferation of the BCL1 B cell lymphoma induced by IL-4 and IL-5 is dependent on IL-6 and GM-CSF. Immunol Cell Biol. 1992;70:315-321.
12. Yee CY, Biondi A, Wang XH, et al. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood. 1989;74:798-805.
13. Shimizu S, Hirano T, Yoshioka R, et al. Interleukin-6 (B-cell stimulatory factor-2)-dependent growth of a Lennert's lymphoma-derived T-cell line (KT-3). Blood. 1988;72:1826-1832.
14. Takeshita M, Sumiyoshi Y, Masuda Y, et al. Cytokine (interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor alpha, and interleukin-6)-possessing cells in lymph nodes of malignant lymphoma. Path Res Pract. 1993;189:18-25.
15. Hsu S-M, Xie S-S, Waldron JA Jr. Functional heterogeneity and pathogenic significance of interleukin-6 in B-cell lymphomas. Am J Pathol. 1992;141:915-922.
16. Freeman GJ, Freedman AS, Rabinowe SN, et al. Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest. 1989;83:1512-1517.
17. Müller H, Takeshita M, Krause J, et al. Immunohistochemical in situ demonstration of cytokines in Hodgkin and non-Hodgkin's lymphoma. Verh Dtsch Ges Pathol. 1992;76:164-169.
18. Emilie D, Devergne O, Raphael M, et al. Production of interleukin-6 in high grade B lymphomas. Curr Top Microbiol Immunol. 1992;182:349-355.
19. Emilie D, Coumbaras J, Raphael M, et al. Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients. Blood. 1992;80:498-505.
20. Foss H-D, Herbst H, Oelmann E, et al. Lymphotoxin, tumor necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases. Br J Haematol. 1993;84:627-633.
21. Kurzrock R, Redman J, Cabanillas F, et al. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993;53:2118-2124.
22. Carbone PP, Kaplan HS, Musshof K, et al. Report of the committee on Hodgkin's disease staging. Cancer Res. 1971;31:1860-1866.
23. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames, IA: Iowa State University Press; 1980.
24. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull. 1945;1:80-85.
25. Kendall MG. Rank Correlation Methods. 4th ed. London: Griffin; 1970.
26. García R, Hernández JM, Caballero MD, et al. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. Br J Cancer. 1993;68:1227-1233.
27. Friedman S, Henry-Amar M, Cosset J-M, et al. Evolution of eryhtrocyte sedimentation rate as predictor of early relapse in posttherapy early-stage Hodgkin's disease. J Clin Oncol. 1988;6:596-601.
28. 2-microglobulin in Hodgkin's disease. J Clin Oncol. 1993;11:1108-1113.
29. Lukes RJ, Butler JJ, Hicks EB. Natural history of Hodgkin's disease as related to its pathologic picture. Cancer. 1966;19:317-322.
30. Hollen CW, Henthorn J, Koziol JA, Burstein SA. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br J Haematol. 1991;79:286-292.
31. Weber J, Yang JC, Topalian SL, et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol. 1993;11:499-505.
32. Blay J-Y, Favrot M, Rossi J-F, Wijdenes J. Role of interleukin-6 in paraneoplastic thrombocytosis. Blood. 1993;82:2261-2268.
33. Black K, Garrett IR, Mundy GR. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology. 1991;128:2657-2663.
34. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans. 1832;17:68-74.
35. Tubiana M, Henry-Amar M, Burgers MV, et al. Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin's Disease. J Clin Oncol. 1984;2:194-199.
36. Samoszuk M, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood. 1990;75:13-19.
37. Seymour JF, Talpaz M, Cabanillas F, et al. Serum interleukin-6 levels correlate with prognosis in diffuse large cell lymphoma. J Clin Oncol. 1995;13:575-582.
38. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621-628.
39. Helle M, Brakenhoff JPJ, De Groot ER, Aarden LA. Interleukin 6 is involved in interleukin 1-induced activities. Eur J Immunol. 1988;18:957-964.
40. Strassmann G, Jacob CO, Evans R, et al. Mechanisms of experimental cancer cachexia. Interactions between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol. 1992;148:3674-3680.
41. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest. 1990;86:592-599.
42. Strassman G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest. 1992;89:1681-1690.
43. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol. 1992;149:2021-2028.
44. 2 interferon involved. Proc Natl Acad Sci USA. 1986;83:8957-8963.
45. Dansky-Ullmann C, Schlom J, Greiner JW. In vivo regulation of carcinoembryonic antigen (CEA) and class I HLA expression in human colon xenografts by interleukin-6 (IL-6) and the possible role of intrinsic interferon-induction. Proc Am Assoc Cancer Res. 1993;34:454. Abstract 2710.
46. Kurzrock R, Quesada JR, Talpaz M, et al. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol. 1986;4:1101-1108.
47. Gause A, Keymis S, Scholz R, et al. Increased levels of circulating cytokines in patients with untreated Hodgkin's disease. Lymphokine Cytokine Res. 1991;11:109-115.
48. Gause A, Jung W, Keymis S, et al. The clinical significance of cytokines and soluble forms of membrane-derived activation antigens in the serum of patients with Hodgkin's disease. Leuk Lymph. 1992;7:439-444.
49. Gause A, Pohl C, Tschiersch A, et al. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood. 1991;77:1983-1988.
50. Blay J-Y, Farcet J-P, Lavaud A, et al. Serum concentrations of cytokines in patients with Hodgkin's disease. Eur J Cancer. 1994;30A:321-327.
51. Ree HJ, Crowley JP, Dinarello CA. Anti-interleukin-1 reactive cells in Hodgkin's disease. Cancer. 1987;59:1717-1723.
52. Gruss H-J, Dölken G, Brach MA, et al. High concentrations of the interleukin-1 receptor antagonist in serum of patients with Hodgkin's disease. Lancet. 1992;340:968-974.
53. Hsu S-M, Zhao X. Expression of interleukin-1 in Reed-Sternberg cells and neoplastic cells from true histiocytic malignancies. Am J Pathol. 1986;125:221-227.
54. Rucco LP, Pomponi D, Pigott R, et al. Cytokine production (IL-1α, IL-1β, and TNFα) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas: An immuunocytochemical study. Am J Pathol. 1990;137:1163-1170.
55. Xerri L, Birg F, Guigou V, et al. In situ expression of the IL-1-α and TNF-α genes by Reed-Sternberg cells in Hodgkin's disease. Int J Cancer. 1992;50:689-695.
56. Perfetti V, Dragani TA, Paulli M, et al. Gene expression of pyrogenic cytokines in Hodgkin's disease lymph nodes. Haematologica. 1992;77: 221-228.
57. Pizzolo G, Chilosi M, Semenzato G. The soluble interleukin-2 receptor in haematological disorders. Br J Haematol. 1987;67:377-383.
58. Pizzolo G, Chilosi M, Vinante F, Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br J Cancer. 1987;55:427-434.
59. Pui C-H, Ip SH, Thompson E, et al. High serum interleukin-2 receptor levels correlate with a poor prognosis in children with Hodgkin's disease. Leukemia. 1989;3:481-489.
60. Ambrosetti A, Nadali G, Vinante F, et al. Serum levels of soluble interleukin-2 receptor in Hodgkin's disease: relationship with clinical stage, tumor burden, and treatment outcome. Cancer. 1993;72:201-209.
61. Smith CA, Gruss H-J, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993;73:1349-1355.
62. Pizzolo G, Nadali G, Vinante F, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. Proc Intl Sac Hematol. 1994;25:205. Abstract 81.
63. Tosato G, Jones KD. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood. 1990;75:1305-1310.
64. Bours B, Dejardin E, Goujon-Letawe F, et al. The NF-KB transcription factor and cancer: high expression of NF-KB and IKB-related proteins in tumor cell lines. Biochem Pharmacol. 1994;47:145-149.
65. Blay J-Y, Negrier S, Combaret V, et al. Serum level of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992;52:3317-3322.
66. Nijsten MW, Dee Groot ER, ten Duis HJ, et al. Serum levels of interleukin-6 and acute phase responses. Lancet. 1987;2:921. Letter.